Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-905/EV-303 perioperative pembrolizumab with or without enfortumab vedotin versus surgery alone in cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer
jRCT2031220686Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and enfortumab vedotin in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC) (3 arms), sponsored by Merck & Co. Primary endpoint: Event-Free Survival. Started Jun 2023; status: active, not recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2031220686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220686.